Sai Parenteral’s Limited is set to launch its Initial Public Offering (IPO) on March 24, 2026. It had filed its Red Herring Prospectus (RHP) on March 16, 2026, with the Securities and Exchange Board of India (SEBI).

The bidding window for Sai Parenteral’s IPO will be open from Tuesday, March 24, to Friday, March 27, 2026. For Anchor Investors, the bidding window will be open from Monday, March 23, onwards.

Sai Parenteral’s Limited is a Hyderabad-based pharmaceutical manufacturing company engaged in the development, manufacturing, and supply of pharmaceutical formulations.

Incorporated in 2001, the company operates across two key verticals—branded generic formulations and contract development and manufacturing (CDMO) services.

Sai Parenteral's IPO - Issue Details

As per the RHP, Sai Parenteral's IPO will be a 100% book-building issue comprising a fresh issue of ₹285 crore and an offer for sale (OFS) of 0.32 crore equity shares, aggregating to ₹123.79 crore.

The IPO price band is fixed at ₹372 to ₹392 per share, and the minimum lot size required for an application is 38.

The allotment process for Sai Parenteral's IPO is expected to be finalised on March 30, 2026, and the shares will be listed on both BSE and NSE, with a tentative listing date of April 2, 2026.

Arihant Capital Markets Limited is the book-running lead manager, and Bigshare Services Private Limited is the registrar of the issue.

Explore other Upcoming IPOs on BSE and NSE.

Utilisation of Proceeds

The Company will utilise the net proceeds from the fresh issue towards the following purposes:

Capacity expansion and upgradation of manufacturing facilities.
Establishment of a new R&D Centre.
Repayment/prepayment of certain outstanding borrowings.
Working capital requirements.
Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
General corporate purposes.

Check out newly Listed IPOs on BSE and NSE.

About Sai Parenteral’s Limited

Sai Parenteral's Limited is engaged in the manufacturing and supply of pharmaceutical formulations. Its product portfolio spans multiple therapeutic areas, including cardiovascular, antidiabetic, antibiotic, gastroenterology, and dermatology, and includes dosage forms such as injectables, tablets, capsules, and liquid orals.

The company caters to a wide range of clients, including government institutions and pharmaceutical companies, and has a strong presence in the sterile injectables and critical care segments. It operates as an unlisted public company with manufacturing and R&D facilities in Telangana.

Financially, the company has witnessed steady growth. Revenue increased from around ₹97 crore in FY23 to about ₹163 - ₹164 crore in FY25, while profit after tax rose to approximately ₹14 crore - ₹15 crore.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.

Do you like this edition?